Oncologists Say They Expect To Prescribe Fotivda for RCC
The renal cell carcinoma (RCC) therapeutic class boasts multiple agents, but a recent entrant is offering a new tool for certain patients. A Zitter Insights survey shows that the majority of oncologist respondents are likely to prescribe Aveo Oncology’s Fotivda (tivozanib) for advanced RCC.
On March 10, the FDA approved Fotivda for the treatment of adults with relapsed or refractory advanced RCC who have received at least two prior systemic therapies. It is the first FDA-approved therapy for this use.
Related Posts

May 11
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed Doses
READ MORE
May 11
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQvia
READ MORE
May 11